These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11744570)

  • 1. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
    Bird SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring clinical trials. Several points are contentious.
    Parry D
    BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring clinical trials. Interim data should not be publicly available.
    Richards SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11778588
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring clinical trials. Caution may be warranted in releasing interim trial data.
    Thornton H
    BMJ; 2001 Dec; 323(7326):1424-5. PubMed ID: 11778589
    [No Abstract]   [Full Text] [Related]  

  • 5. When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.
    De Rossi C; Brunello A; Jirillo G; Jirillo A
    Immunopharmacol Immunotoxicol; 2009; 31(1):1-4. PubMed ID: 19238693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 8. Ethical issues with the disclosure of surgical trial short-term data.
    Allardyce RA; Bagshaw PF; Frampton CM; Frizelle FA; Hewett PJ; Rieger NA; Smith JS; Solomon MJ; Stevenson AR
    ANZ J Surg; 2011 Mar; 81(3):125-31. PubMed ID: 21342382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring clinical trials. Interim data are at least as important as interim analyses.
    Reidpath D
    BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778591
    [No Abstract]   [Full Text] [Related]  

  • 11. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 12. When should an interim analysis be unblinded to the data monitoring committee?
    Knottnerus JA; Spigt MG
    J Clin Epidemiol; 2010 Apr; 63(4):350-2. PubMed ID: 19762210
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 14. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic beneficence and patient recruitment in randomized controlled clinical trials.
    Mann H
    Am J Bioeth; 2002; 2(2):35-6. PubMed ID: 12189074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.